Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GDC-0575 |
| Synonyms | |
| Therapy Description |
GDC-0575 selectively inhibits CHK1, which potentially results in increased response to chemotherapeutic agents (PMID: 29162833, PMID: 29788155). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GDC-0575 | ARRY-575|RG7741 | CHK1 Inhibitor 18 | GDC-0575 selectively inhibits CHK1, which potentially results in increased response to chemotherapeutic agents (PMID: 29162833, PMID: 29788155). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01564251 | Phase I | GDC-0575 + Gemcitabine GDC-0575 | A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | Completed | USA | FRA | 0 |